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ABSTRACT 
BACKGROUND:  Genistein capsules are currently being developed to treat osteo- 
porosis in China. Genistein is extracted from the fruit of Sophora j ponica Leguminosae. 
OBJECT IVE:  The objective of this study was to assess the pharmacokinetics of 
genistein capsules after single and multiple oral doses in healthy Chinese subjects. 
METHODS:  This was a Phase I, randomized, open-label, single- and multiple- 
dose study in healthy Chinese adults (aged 19/40 years). In the single-dose study, 
subjects were randomly assigned in a 1:1:1 ratio to receive genistein 50, 100, or 300 mg 
(in 50-mg capsules). To assess the effect of food on the pharmacokinetics, subjects in 
the 50-mg group were equally randomized again into fasting and postprandial (geni- 
stein was administered after a high-fat breakfast) groups according to a 2-way cross- 
over design. A separate qual-sized group of subjects were administered genistein 
50 mg on day 1 (single dose), received no treatment on days 2 and 3, and were ad- 
ministered genistein 50 mg QD for 6 days (days 4 9) to obtain a multiple-dose phar- 
macokinetic profile. Because genistein is converted so rapidly and completely to 
glucuronidated genistein after administration, plasma concentrations of glucuronidated 
genistein were determined using a validated high-performance liquid chromatography/ 
tandem mass spectrometry method. Drug tolerability was assessed by monitoring 
adverse vents (AEs) and laboratory parameters. 
RESULTS:  The study enrolled 40 healthy subjects (24 men, 16 women; 10 each 
in the 50-, 100-, and 300-mg single-dose groups and 10 in the multiple-dose group). 
Three subjects voluntarily withdrew (2 in the 100-mg group and 1 in the 300-mg group) 
before study drug administration. Thirty-seven subjects (24 men, 13 women) 
completed the study and were included in the analysis. The mean (SD) values of the 
single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tma~, 6.0 (2.4), 
7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 
9.4 (1.1) hours; AUC 0 t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL - h 1; 
and C .... , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL. The plasma 
glucuronidated genistein concentrations were directly proportional to the adminis- 
tered dose over the range of 50 to 100 mg and increased nonproportionately with 
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the 300-mg dose. No statistically significant differences in pharmacokinetic pa- 
rameters were found in the fasting group compared with the postprandial group. In 
the multiple-dose group, the mean (SD) steady-state pharmacokinetic parameters 
on day 9 were similar to those following a single dose of genistein on day 1 (Tma~, 
6.0 [1.0] vs 5.9 [1.5] hours, respectively; tl/2, 9.5 [1.5] vs 9.1 [1.5] hours; 
AUC0 t, 2830 [1541] vs 2078 [1308] ng/mL - h 1; C .... , 203.1 [130.9] vs 
168.4 [105.7] ng/mL). All AEs were assessed as mild or moderate and resolved 
without treatment, with the exception of elevated alanine aminotransferase and as- 
partate aminotransferase activities in one subject that resolved with treatment. 
CONCLUSIONS:  The pharmacokinetics of glucuronidated genistein appeared to 
fit the linear-dose range ofgenistein 50 to 100 mg, but not the 300-mg dose in these 
healthy Chinese volunteers. Food consumption did not significantly affect the phar- 
macokinetic properties. No significant differences were observed in the pharmacoki- 
netic parameters after multiple doses of genistein compared with a single dose, sug- 
gesting that the drug did not accumulate after multiple doses. (Curr Ther Res Cli~l Exp. 
2008;69:318 333) © 2008 Excerpta Medica Inc. 
KEY WORDS:  pharmacokinetics, genistein capsule, single dose, multiple dose, 
healthy Chinese subject. 
INTRODUCTION 
Osteoporosis  a common disease in postmenopausal women. 1,2 Estrogen replacement 
therapy has been used for the treatment of osteoporosis. 2'3However, long-term use of 
estrogen might increase the risk for stroke and the prevalence ofendometrial cancer. 4,5 
Isoflavones have been found to be beneficial in preventing osteoporosis, while being 
associated with fewer adverse vents (AEs). 6 Epidemiologic studies have suggested 
that the prevalence of osteoporosis n Asian populations i lower than that in Western 
populations, possibly because of long-term consumption of isoflavones (eg, soybeans 
and soy foods such as tofu, soy milk, soy flour). As one of the main active components 
of isoflavones, genistein has been found to improve bone mineral density (BMD), in- 
crease the number ofosteoblasts, prevent he formation ofosteoclast-like c ils, inhibit 
bone resorption, and reduce bone loss .  7 10 No human trials have been published that 
suggest a benefit of this osteoporosis treatment. 
The chemical structure (4',5,7-trihydroxy-isoflavone) a d properties of genistein 
are similar to those of estradiol (Figure 1).11 Genistein is glucuronidated or sulfated 
in the intestine after oral administration. In vivo testing of genistein found that 
genistein glucuronide was its primary metabolite. 1214 Because genistein is converted 
so rapidly and completely to glucuronidated genistein after administration, plasma 
concentrations of glucuronidated genistein rather than genistein tself are usually 
measured. 
In China, genistein capsules are currently under development to be used to treat 
osteoporosis. The main constituent is genistein (purity >98%), which is extracted 
from the traditional Chinese medicine fruit of Sophora j po~lica Legumi~losae. 15 We per- 
formed a search of the English-language literature in MEDLINE (1998 2008) using 
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Figure 1. Chemical structure of (A) genistein and (B) estradiol. 
the following search terms: genistein capsule, single dose, multiple dose, and pharmacokinetics. 
In preclinical studies, genistein was associated with improved BMD and concentra- 
tions of trace elements in a retinoic acid-induced rat model, 16 ameliorated femur bio- 
mechanics and enhanced BMD in ovariectomized rats, 17 and inhibited osteoporosis. 15 
Some experimental data are also available on the pharmacokinetics of genistein cap- 
sules.18 20 After administration ofgenistein capsules at different doses in beagles, the 
drug was found primarily in the form of glucuronidated genistein (73% 83%) in 
plasma. 18 With increasing doses, the absorption ofgenistein became saturated and the 
tl/2 prolonged, while the AUC of glucuronidated genistein increased in proportion to 
the dose. In rats, the oral bioavailability of genistein capsules was found to be 
56.49%.19 Genistein was found to be excreted mainly in the form of glucuronidated 
genistein in rat bile in a nonlinear, dose-dependent manner. 2° However, the pharma- 
cokinetic profile ofgenistein capsules after single and multiple oral administration has 
not yet been reported in humans. The dose proportionality of the plasma drug con- 
centrations over the therapeutic range has also not been determined. 
The purpose of this study was to assess the pharmacokinetics of genistein capsules 
(Institute of Materia Medica of The Fourth Military Medical University, Xian, China) 
after single escalating oral doses (50, 100, and 300 mg) and multiple doses (50 mg QD) 
in healthy Chinese subjects, as well as the effect of food intake on genistein pharma- 
cokinetics. A better understanding of the pharmacokinetics of genistein capsules will 
facilitate the design of future clinical trials and provide a scientific basis for the evalua- 
tion of this preparation. 
SUBJECTS AND METHODS 
S U BJ ECTS 
All subjects provided written informed consent prior to study participation. 
Through local advertising, the investigators ecruited healthy men and women aged 
19 to 40 years to participate in the study. Forty subjects were enrolled according to 
the following inclusion criteria: (1) body mass index of 19 to 25 kg/m 2 (inclusive); 
(2) normal vital signs, physical examination findings, and results on standard labora- 
tory tests, including hematology (erythrocytes, leukocyte total and differential cell 
counts, platelets, hemoglobin, and hematocrit), blood chemistry (creatinine, blood 
urea nitrogen, alanine aminotransferase [ALT], aspartate aminotransferase [AST], al- 
kaline phosphatase, total bilirubin), and urinalysis (pH, glucose, hemoglobin, blood, 
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protein); (3) normal results on 12-lead electrocardiography (ECG), thyroid gland 
ultrasonography, and chest fluoroscopy; (4) no history of renal, hepatic, gastrointes- 
tinal, cardiovascular, hematologic, nervous, or psychological disease; (5) no history 
of allergy to any components of genistein capsules; (6) no report of smoking or al- 
cohol or drug addiction before or during the study (determined by investigator in- 
quiry, subject report, and urine screening); (7) female subjects could not be preg- 
nant or menstruating (determined by subject report); (8) no use of drugs or other 
medications and o participation in a clinical trial that might interfere with the 
pharmacokinetics ofgenistein or be harmful to human organs 3 months before or dur- 
ing the study; and (9) negative results for hepatitis B surface antigen or hepatitis C 
virus antibody tests. 
STUDY DES IGN 
The study was conducted at Guangdong Provincial Hospital of Traditional Chinese 
Medicine (TCM) (Guangzhou, China) in accordance with the Declaration f Helsinki 
and the Guideline for Good Clinical Practice. The study protocol was approved by the 
Medical Ethical Committee of Guangdong Provincial Hospital of TCM. 
In the single-dose study, subjects were randomized using a computer-generated table 
of random numbers at a 1:1:1 ratio into 1 of 3 treatment groups (genistein 50, 100, 
and 300 mg). Each subject received the dose orally with 200 mL of water after an 
overnight fast. Water intake was allowed 2 hours after administration, and standard 
meals were provided at 4 and 10 hours after administration. 
To assess the effect of food on genistein pharmacokinetics, the subjects in the 
50-mg dose group were evenly randomized to the fasting or postprandial state (2 sub- 
groups) according to a 2-way crossover design. In the first study period, half of the 
subjects received 50 mg ofgenistein in a fasting state; the remaining subjects received 
50 mg of genistein after a high-fat breakfast (-820 kcal). After a washout period of 
1 week, the 2 subgroups crossed over and received genistein in the alternate manner. 
In the 50-, 100-, and 300-mg groups, blood samples (4 mL) were collected in hepa- 
rinized tubes at 0 hour (before administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 
6, 7, 8, 12, 16, 24, 36, and 48 hours after administration. 
In the multiple-dose study, a fourth group of subjects were administered 
genistein 50 mg orally on day 1, received no treatment on days 2 and 3, and were 
administered genistein 50 mg orally QD for 6 days (days 4 9). Water intake was 
allowed 2 hours after administration, and standard meals were provided at 4 and 
10 hours after administration. On days 6, 7, 8, and 9, 4 mL of venous blood was 
collected before genistein administration to determine the minimum value of the 
steady-state plasma drug concentration (Cmi .... ). On days 1 and 9, blood samples 
were obtained at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 16, 24, 36, and 
48 hours after administration. 
All blood samples were separated by centrifugation at 3000 rpm for 10 minutes; 
plasma samples were then collected and stored at 75°C until analysis. 
During the test period, all subjects were kept in the study unit and observed con- 
tinuously. Identical food and water were served. The subjects were required to refrain 
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from smoking and drinking alcohol or caffeine-containing beverages and were in- 
structed to consume no soy products. Strenuous exercise was not allowed. 
DRUG ANALYS IS  
The plasma genistein concentration was determined using a validated high- 
performance liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. 
Dexamethasone (National I stitute for the Control of Pharmaceutical nd Biological 
Products, Beijing, China) was selected as the internal standard (IS). To each 300-1aL 
plasma sample, 25 laL of dexamethasone solution (500 ng/mL) and 200 laL of ammoni- 
um acetate solution were added and mixed, and then 3 mL of ethyl acetate was added. 
The mixture was vortexed for 2 minutes and centrifuged at 3000 rpm for 10 minutes. 
The supernatant was transferred, evaporated until dry, and reconstituted with 150 laL 
of mobile phase, 20 laL of which was then injected to determine the plasma concen- 
tration of the unchanged genistein. Another 300-1aL plasma sample was incubated 
with ~-glucuronidase (1000 U/mL) at 37°C for 24 hours and then pretreated as de- 
scribed above to measure total genistein (ie, unchanged genistein plus glucuronidated 
genistein). In this study, the plasma genistein concentration was so low that un- 
changed genistein could not be detected in many samples. Glucuronidated genistein 
was the main form in which genistein was detected in plasma. 
The analytes were separated on a C8 column (Capcell Pak, Phenomenex, Torrence, 
California; 2.0 x 150 mm; 5 ~nn) by isocratic elution with methanol:ammonium ace- 
tate 5 mmol/L:acetonitrile (70:20:10, v/v/v) at a flow rate of 220 laL/min and quanti- 
fied using the positive ion mode in a triple quadrupole mass spectrometer (API 3000, 
Applied Biosystems, Foster City, California). The fragmentation transitions for the 
multiple reaction monitoring were m/z 271.0--9153.0 for genistein and m/z 
393.2 --9237.4 for IS. In comparing the chromatograms of 6 different batches of blank 
human plasma with the corresponding spiked plasma, no interference of endogenous 
components in plasma with the detection ofgenistein and IS was found. The weighted 
(1/x 2) calibration curves were linear over the concentration range of 0.3 to 500 ng/mL 
in plasma, with correlation coefficients >0.9952. The lower limit of quantification 
was 0.3 ng/mL. The inter- and intrabatch precisions were <7% for quality control 
(QC) samples at 3 concentrations ranging from 0.9 to 400 ng/mL, the method recov- 
eries were 92.9% to 104.9%, and the extraction recoveries were 74.2% to 89.2%. 
Genistein in human plasma was found to be stable under the following conditions: at 
room temperature for 6 hours; after 3 freez~thaw cycles; at 75°C for 5 months; and 
at room temperature for 6 hours and at 4°C for 24 hours after a sample had been pre- 
pared in reconstituted reagent. The samples were determined once, but those in doubt 
were reanalyzed. As stated previously, the samples were determined using LC/MS/MS 
accompanied by QC samples at 3 concentrations (low, medium, and high). At least 
2 QC samples at each concentration were included in each batch. When the number 
of unknown samples was > 120, the total number of QC samples hould be increased 
to >5% of the unknown samples. All QC samples hould fall within + 15% of the 
theoretic value to be accepted, except at the lowest concentration, i  which +20% was 
acceptable. For a batch to be valid, two thirds of the QC samples (in each of the 
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3 concentrations) must fall within the acceptable range. If this condition was not met 
in a particular batch, the results of the samples analyzed in that batch were classified 
as "in doubt" and reanalyzed. In addition, if the sample concentration at the later time 
point in the elimination phase of the drug concentration time curve was significantly 
higher than that at the earlier time point, the sample was reanalyzed to exclude the 
possibility of a mistake in sample preparation. The decision to reanalyze a sample was 
made by a QC investigator. In this study, 7 samples were reanalyzed. 
PHARMACOKINET IC  ANALYS IS  
The plasma concentration time data for each subject were analyzed by noncom- 
partmental techniques using Drug and Statistic software version 2.0 (Rui-yuan Sun, 
Wuhu, China). All calculations of plasma pharmacokinetics were based on actual 
sampling times. The pharmacokinetic parameters calculated included tl/2, clearance 
(CL), apparent volume of distribution, and mean residence time from time 0 to 
time t (MRT 0 t)" The Cma ~ and Tma ~ of the single-dose study, as well as the C~ .... and 
maximum values of the steady-state plasma drug concentration (Cma~_ss), were derived 
directly from the observed ata. 21,22 The AUC0~ was calculated using the linear trape- 
zoidal rule. 23 The AUC extrapolated to infinity (AUC 0 ~) was calculated as follows: 
AUC0 ~ + C~/5~ z, 
where C t was the last detectable concentration and 5~ was the apparent elimination 
constant estimated by linear regression of the log-transformed plasma concentrations 
during the terminal og-linear declining phase. The average steady-state concentra- 
tion was calculated as follows: 
AUC 0 z/'C, 
where z was the dosing interval. The degree of fluctuation was calculated as follows: 
(C ....... Cmi .... )/gay" 
STAT IST ICAL  ANALYS IS  
Statistical analyses were performed using SPSS software version 11.0 (SPSS, Inc., 
Chicago, Illinois). Results were expressed as mean (SD). The CV was calculated to 
determine the variability of the pharmacokinetic parameters. The differences in phar- 
macokinetic parameters between the concentrations in each single-dose group and 
between the fasting and postprandial groups were compared using analysis of vari- 
ance. If P < 0.05, the Mann-Whitney U test was used to perform further pairwise 
comparisons between groups. Comparisons between the data on day 9 (multiple dose) 
and the data on day 1 (single dose) of the subjects in the multiple-dose group were 
conducted using the paired t test. P < 0.05 was considered statistically significant. 
Based on clinical guidelines for sample sizes of groups in a Phase I pharmacokinetic 
study, we determined that 10 subjects per group would be sufficient. Furthermore, 
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because the tolerability ofgenistein capsules has not been determined, a larger sample 
size was considered inappropriate. In this study, the sample size in each group was decided 
to be 10 according to the Guidance for Clinical Pharmacokinetic Study of Chemicals in 
China. In the guidance, the sample size in each dose group in a Phase I pharmacokinetic 
study in healthy volunteers i 8 to 12, which provides a power of 80% to reject the null 
hypotheses at 1-sided significance l vels of 5 % in favor of the alternative hypotheses. 
TOLERABIL ITY  ASSESSMENT 
Throughout the study, all subjects remained in the study unit under continuous 
observation. Subjects' symptoms, objective signs, and vital signs (ie, blood pressure, 
heart rate, respiratory rate, and body temperature) were checked before and 1, 4, 8, 
24, and 48 hours after administration i the single-dose groups, and before each ad- 
ministration and 1, 12, 24, and 48 hours after the first and last administrations in the 
multiple-dose group. Routine hematology, blood chemistry, urinalysis, thyroid gland 
ultrasonography, and ECG were performed before administration and 48 hours after 
administration i  the single-dose groups, and before administration and 48 hours af- 
ter the final administration i the multiple-dose group. AEs were assessed by the in- 
vestigator as to their intensity, seriousness, and relationship to the study drug. 
RESULTS 
STUDY POPULAT ION 
Forty healthy Chinese subjects were enrolled and randomized to treatment. Thirty- 
seven subjects (24 men, 13 women) completed the study. Three subjects (2 in the 
100-mg group and 1 in the 300-mg group) voluntarily withdrew from the study on 
day 1 before drug administration, for personal reasons. Two subjects (1 each in the 
100- and 300-mg groups) had changes in plasma drug concentrations that differed 
substantially from the other subjects. The data for these 2 subjects were not included 
in the pharmacokinetic calculations or the statistical analyses. The demographic char- 
acteristics of the study population are presented in Table I. The demographic charac- 
teristics in the single-dose groups were similar. 
S INGLE-DOSE PHARMACOKINET ICS  
After oral administration f genistein 50 mg in the postprandial state and genistein 50, 
100, and 300 mg in the fasting state, genistein appeared rapidly in plasma nd was biomodi- 
fled immediately. The plasma-undmnged genistein concentrations were low (Figure 2A). 
Glucuronide conjugate was the main form of genistein in plasma. Mean (SD) pharma- 
cokinetic profiles of glucuronidated genistein after a single dose are shown in Figure 2B. 
The pharmacokinetic parameters ofglucuronidated genistein are reported in Table II. 
Mean C .... and AUC increased in proportion to dose, and there were no significant 
difterences in the mean values of Cm /dose and AUC/dose between the 50- and 
100-rag groups. After the administration fgenistein 50 and 100 rag, the mean values 
of T .... (6.0-7.4 hours) and tl/2 (12.6-13.0 hours) appeared to be independent of 
dose; mean values of CL and 5~ zwere 17.2 to 17.8 L/h and 277 to 322 L, respective- 
ly. Therefore, the pharmacokinetics of glucuronidated genistein appeared to fit the 
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Table I. Demographic characteristics of healthy Chinese subjects randomized to treat- 
ment with genistein in either a single- or multiple-dose study (N = 37).* 
Single-Dose Groups 
Multiple-Dose 
Group 
50 mg 100 mg 300 mg 50 mg 
Characteristic (n = 10) (n = 8) (n = 9) (n = 10) 
Age, y 
Mean (SD) 24.4 (1.1) 25.2 (1.3) 24.0 (1.7) 23.9 (3.2) 
Range 23-26 24-27 22-27 21-31 
Sex, no. (%) 
Male 6 (60.0) 6 (75.0) 6 (66.7) 6 (60.0) 
Female 4 (40.0) 2 (25.0) 3 (33.3) 4 (40.0) 
Weight, kg 
Mean (SD) 57 (10) 62 (8) 57 (7) 59 (7) 
Range 45-68  51-69 45-69  49-72 
Height, cm 
Mean (SD) 163 (8) 167 (5) 166 (7) 167 (7) 
Range 152-172 161-172 150-177 158-175 
BMI, kg/m 2 
Mean (SD) 21.6 (1.5) 22.1 (1.6) 20.9 (1.5) 21.1 (2.4) 
Range 19-23 20-24 19-24 19-25 
BMI = body mass index. 
*No significant between-group differences were found. 
linear dynamic feature in the dose range of 50 to 100 mg. In the 300-mg group, 
C .... and AUC increased nonproportionally, suggesting nonlinear kinetic character- 
istics. According to analysis of variance and the Student test, no statistically sig- 
nificant differences in the pharmacokinetic parameters were found between the 
fasting and postprandial groups, indicating that food consumption did not affect 
the drug's dynamic properties in vivo. 
In the single-dose study, the CV percentages for AUC 0 t, AUC0 ~, and Cma ~ were 
48.89%, 54.86%, and 31.35%, respectively, in the 50-mg fasting group; 56.73%, 
63.09%, and 46.01% in the 50-mg postprandial group; and 61.56%, 73.24%, and 
46.38% in the 100-mg group. In the 300-mg group, the CV percentages for these 
pharmacokinetic parameters were all < 28%. 
MULTIPLE-DOSE PHARMACOKINET ICS  
After consecutive days of genistein 50-mg administration, the mean Cmi n of glu- 
curonidated genistein on days 6, 7, 8, and 9 was 39.1, 39.5, 43.7 and 46.1 ng/mL, 
respectively (Figure 3). There were no statistically significant differences between 
these values. 
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Figure 2. Mean (SO) plasma concentration-time curves of (A) genistein and (B) 
glucuronidated genistein in healthy Chinese subjects after a single oral dose of 
genistein ( 50°mg group, n = 10; lO0-mg group, n = 7; 300-rag group, n = 8). 
- nidated genistein concentration-time curves after the 
The mean plasma glucurO L a..~ gdav 9) were simitar in shape (Figure 4). No 
first dose (day 1) and me tast m, . . . .  parameters were found between 
significant differences in the pharmacokinetic day l and day 9 (Table l lD (by paired t test), indicating that the steady-state 
pharmacokinetic parameters of glucuronidated genistein were simitar to those 
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Table II. Mean (SD) pharmacokinetic parameters of glucuronidated genistein in healthy 
Chinese subjects after a single oral dose of genistein (N = 25). Data are 
mean (SD). 
50-mg Group 
(n = lO)  
Parameter Postprandial Fasting 
lO0-mg 300-mg 
Group Group 
(n = 7) (n = 8) 
Tmax, h 6.7 (2.3) 6.0 (2.4) 7.4 (2.4) 5.6 (1.2) 
tl/2, h 10.9 (3.4) 13.0 (4.0) 12.6 (5.8) 9.4 (1.1) 
CL, L/h 15.8 (8.2) 17.2 (8.3) 17.8 (14.7) 32.8 (8.9) 
V d, L 227.1 (99.6) 322.4 (217.1) 277.1 (218.4) 444.2 (125.9) 
AUCo_t,* ng/mL • h -1 3951 (2241) 3344 (1635) 8389 (5164) 9361 (2428)t 
AUCo_~,* ng/mL • h -1 4306 (2716) 3703 (2031) 9787 (7167) 9736 (2553)t 
MRTo_ t, h 14.7 (2.9) 14.6 (2.2) 16.0 (3.2) 14.6 (0.9) 
MRTo_ ~, h 18. 5 (6.7) 19.3 (4.4) 20.4 (7.4) 16.5 (1.3) 
Cmax,* ng/mL 220.5 (101.4) 218.7 (68.6) 435.7 (202.1) 553.4 (152.8)t¢ 
CL = clearance; V d = apparent volume of distribution; MRTo~ = mean residence time from 
time t; MRTo~  = mean residence time from time 0 to infinity. 
*Adjusted for dose. 
tp < 0.05 versus the 50-mg fasting group. 
CP < 0.05 versus the lO0-mg group. 
time 0 to 
IO0  
8O 
60 t
2O 
0 i I I I 
6 7 8 9 
Time (d) 
Figure 3. Mean (SD) Cml n of glucuronidated genistein in healthy Chinese subjects after 
multiple doses of genistein 50 mg QD (n = 10). 
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Figure 4. Mean (SD) plasma concentration-time curves of glucuronidated genistein in 
healthy Chinese subjects after multiple doses of genistein 50 mg QD (n = 10). 
Table III. Mean (SD) pharmacokinetic parameters of glucuronidated 
genistein in healthy Chinese subjects after multiple doses of 
genistein 50 mg (n = 10).* 
Parameter Day 1 Day 9 
Tmax, h 5.9 (1.5) 6.0 (1.0) 
tl/2, h 9.1 (1.5) 9.5 (1.5) 
CL, L/h 34.3 (23.2) 23.8 (15.0) 
V d, L 473.5 (368.3) 331.3 (235.7) 
AUCo_t, ng/mL • h -1 2078 (1308) 2830 (1541) 
AUCo_ ~, ng/mL • h -1 2127 (1325) 2920 (1593) 
MRTo_ t, h 12.6 (0.9) 13.2 (0.8) 
MRTo_ ~, h 13.9 (1.1) 14.9 (0.6) 
Cma x, ng/mL 168.4 (105.7) 203.1 (130.9) 
Cmin-ss, ng/mL 46.1 (32.1) 
Cav, ng/mL 99.6 (55.5) 
DF 1.5 (0.3) 
CL = clearance; V d = apparent volume of distribution; MRTo4 = mean residence 
time from time 0 to time t; MRTo~  = MRT from time 0 to infinity; Cmins s = minimum 
plasma concentration at steady state; Cav = average concentration at steady state; 
DF = degree of fluctuation. 
*No significant between-day differences were observed. 
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after a single dose and that no accumulation was found after multiple doses of 
genistein. 
In the multiple-dose group, the CV percentages for the pharmacokinetic parame- 
ters were all >50%. 
TOLERABIL ITY  
No serious clinical AEs were found in the single-dose study. Abnormalities on 
routine urinalysis were found in 2 subjects in the 50-mg group (fasting and postpran- 
dial) (elevated white blood cell count [ -12 25 cells/laL] and nitrite positive in 1 sub- 
ject and elevated white blood cell count [< 12 cells/laL] in the other subject, which 
lasted -1 day). Abnormalities on ECG (mild changes in T waves, which returned to 
normal after 1 day) were observed in 1 subject in the 50-mg group, and mildly ele- 
vated thyroid-stimulating hormone (TSH) concentrations were observed in 1 subject 
each in the 50- and 300-mg groups (8.63 and 5.79 mlU/L, respectively) and returned 
to normal after 2 weeks and 8 days, respectively, without treatment. One subject in 
the 100-mg group experienced nausea nd vomiting of moderate severity after admin- 
istration; the symptoms improved after 20 hours. The same subject had abnormal 
findings on urinalysis (elevated total bilirubin, -17 50 ~tmol/L), which returned to 
normal after 24 hours. These AEs were judged by the study investigator to probably 
be associated with the study drug; however, none of the subjects were withdrawn from 
the study. Other laboratory values from subjects in the single-dose groups were within 
the normal range. 
In the multiple-dose group, 6 AEs were reported in 5 subjects. Abnormal routine 
urinalysis was observed in 1 subject 48 hours after the final administration (elevated 
red blood cell count [ -150 250 cells/laL], which was judged to be associated with 
menstrual onset and which had returned to normal when rechecked after 4 days). 
Three subjects had abnormal ECG (sinus arrhythmia, which had returned to normal 
when rechecked after 1 day). These AEs were judged not to be associated with the 
study drug by the investigator. Elevated TSH concentration (6.04 mlU/L) was ob- 
served in 1 subject 48 hours after the last administration. The same subject also expe- 
rienced increases in ALT (134 IU) and AST (58 IU) activities, which returned to normal 
with treatment (glucurolactone 0.2 g TID for 6 days; normal saline 100 mL for IV 
hydration; reduced glutathione sodium 0.6 g IV drip QD for 5 days; 500-mL glucose 5%; 
vitamin C 2.0 g intravenous drip QD for 5 days; followed by outpatient treatment with 
glucurolactone 0.2 g TID for 7 days). This event was considered to be probably associated 
with the study drug. Other laboratory values from subjects in the multiple-dose groups 
were within the normal range. 
DISCUSSION 
This study presents new information on the pharmacokinetic profile of genistein. 
Although some data on genistein pharmacokinetics have been reported in previous 
studies, 3,24 the pharmacokinetics of genistein capsules after oral administration, espe- 
cially after multiple oral administration, and the pharmacokinetic effects of genistein 
dose escalation had not been fully addressed. Our results suggest hat glucuronidated 
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genistein was the primary existing form ofgenistein in plasma. The AUC and plasma 
concentration of the drug increased linearly when the dose was increased from 50 to 
100 mg; however, the increase was nonlinear when the dose was increased to 300 mg. 
Similar pharmacokinetic properties were found in comparing the single-dose with the 
multiple-dose profile. 
In this study, genistein and its glucuronide conjugate were detected in plasma 
15 minutes after oral administration ofgenistein capsules in healthy subjects, indi- 
cating that genistein was rapidly absorbed and converted to glucuronidated 
genistein. By comparing the concentrations of unchanged and glucuronidated 
genistein, we found that the plasma concentration of the unchanged rug was low 
and that the drug primarily ( -98%) existed as genistein glucuronide in human 
plasma. With the 50-mg dose, the plasma glucuronidated genistein concentration 
time curves of 3 subjects had a biphasic pattern, but the mean concentration time 
curve did not. In the 100- and 300-mg groups, the mean plasma drug concentration 
time curves also demonstrated a biphasic pattern with a less evident first peak, 
which might have resulted from enterohepatic recirculation and was in agreement 
with previous reports. 3,25 
Our study presents a detailed pharmacokinetic nvestigation of genistein cap- 
sules in healthy Chinese subjects. The mean T .... of glucuronidated genistein after 
a single dose ofgenistein occurred at 5 to 7 hours, similar to that reported in previ- 
ous studies. 3'24'26 The mean tl/2 was numerically longer than values (7 8 hours) 
reported by others .  3'24'27 This difference might result from variations in age, race, 
metabolic enzymes, or other factors. Setchell et a124'2s observed that the bioavail- 
ability of genistein did not increase linearly when the dose (0.4 mg/kg) was dou- 
bled. In our study, the mean values of C .... /dose, AUC/dose, and other parameters 
did not differ significantly between the 50-mg and the 100-mg group. In the 
300-mg group, the C .... and AUC did not increase in proportion to the dose and 
nonlinear pharmacokinetics were exhibited. When the increase in AUC is smaller 
than that expected on the basis of a linear relationship, it is indicative either of 
increased elimination or reduced absorption. An uptake experiment which was de- 
signed to investigate the absorption mechanisms of genistein using human colon 
carcinoma cell line, Caco-2 cells, revealed that the transcellular transport of 
genistein was saturable and dose-dependent29; the same phenomenon was noted in 
a preclinical pharmacokinetic study in beagles, is Therefore, the saturable absorp- 
tion of genistein at high doses is thought to be the main reason that the AUC in- 
creases nonproportionally with increasing dose. 
Three subjects (2 in the 100-mg group and 1 in the 300-mg group) withdrew 
voluntarily from the study before drug administration. The 2 subjects (1 each in the 
100- and 300-mg groups) who had changes in plasma drug concentrations that dif- 
fered substantially from the other subjects were not included in the pharmacokinetic 
calculations or the statistical analyses. The plasma glucuronidated genistein concen- 
trations remained high and did not decrease significantly at the end of the elimination 
phase; the drug elimination rate was slow (Figure 5). Cytochrome P450 (CYP) 1A2 
has been reported to be involved in genistein metabolism. 3° It is possible that the 
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Figure 5. Plasma concentration-time curves of glucuronidated genistein in 2 subjects 
whose concentrations were still high at the end of the elimination phase after 
a single oral dose of genistein 100 mg and 300 mg. 
gene polymorphism of CYP1A2 might have resulted in the observed ifference in 
drug elimination. Further investigations will be needed to determine this. 
Compared with subjects in the fasting roup, T .... was numerically prolonged 
in the postprandial group, but the difference was not significant. AUC, tl/2, 
CL/F, MRT, and C .... were similar in the 2 groups, indicating that food did 
not affect the absorption and elimination of glucuronidated genistein after oral 
administration. 
In the multiple-dose study, the Cmi .... was achieved on day 6. The pharmacokinetic 
parameters of glucuronidated genistein were similar to those after a single dose of 
genistein, without significant drug accumulation after 6 days of QD administration 
ofgenistein 50 mg. 
Based on the CV percentages in the single-dose group, there was great intersubject 
variation in the pharmacokinetics ofgenistein capsules, especially over the dose range 
of 50 to 100 mg. 
None of the 37 participants withdrew from the study prematurely because of 
genistein intolerance. All AEs were mild or moderate, with abnormalities in urinaly- 
sis, ECG, and TSH concentration being reported in 11 subjects. Moderate nausea nd 
vomiting were observed in 1 subject; elevated transaminase activities (ALT and AST) 
were observed in 1 subject and resolved with treatment. A clear relationship between 
dose and AEs was not observed in the study; caution and further observation of 
treatment-emergent AEs associated with genistein capsules are needed in future clini- 
cal trials. 
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L IM ITAT IONS 
The small number of subjects might have resulted in large individual variation. 
The 6 consecutive days of administration were not enough to assess the long-term 
tolerability of genistein capsules. Subjects in this Phase I study were healthy young 
men and women, so further long-term studies are needed to assess the pharmacokinet- 
ics and tolerability of genistein capsules in other populations. 
CONCLUSIONS 
The pharmacokinetics of glucuronidated genistein appeared to fit the linear-dose 
range of 50 to 100 mg, but not the 300-mg dose. Food consumption did not affect 
the pharmacokinetic properties ignificantly. There was no significant difference ob- 
served in the pharmacokinetic parameters following multiple doses compared with a 
single dose, suggesting that the drug did not accumulate after multiple doses. 
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